# AOD-9604 FAQ: Questions About the hGH Fragment 176-191 Research Record

> AOD-9604 FAQ: 25 questions on mechanism, safety, dosage, regulatory status, and research outcomes — every answer sourced from the clinical and preclinical literature.

Twenty-five questions on mechanism, dosage, clinical trials, safety, and regulatory status — each answered directly from the published literature.

## What is AOD-9604?

A synthetic 16-amino-acid peptide corresponding to the C-terminal residues 176–191 of human growth hormone, with a tyrosine substituted at the N-terminal position. Molecular formula C78H123N23O23S2, MW 1815.1 Da. Studied for fat-metabolism effects across preclinical models and six human clinical trials.

## What is AOD-9604 used for?

Primarily studied for lipolysis and fat metabolism in obesity research — the compound's original pharmaceutical development target. Secondary investigation has examined cartilage regeneration and osteoarthritis: a 2015 rabbit intra-articular study [14] and an active Phase 2a human trial (NCT07225829) for knee osteoarthritis with synovitis. A 2022 in-vitro study also investigated the peptide sequence in a cancer-cell cytotoxicity context [15].

## What does AOD-9604 do?

Proposed to inhibit acetyl-CoA carboxylase (suppressing fatty acid synthesis) via a plasma-membrane second-messenger mechanism [3], and to upregulate beta-3 adrenergic receptor mRNA in adipose tissue (promoting cAMP-mediated lipolysis) [6]. It does not bind the hGH receptor and does not stimulate IGF-1 or insulin-like growth signals. Reduced glucose uptake in isolated rat adipocytes was also documented in vitro [4].

## How does AOD-9604 work?

AOD-9604 binds to adipocyte membrane receptors distinct from the hGH receptor and activates lipolysis pathways. It is structurally identical to the lipolytic domain of hGH but lacks the IGF-1-stimulating N-terminal region. It inhibits fatty acid biosynthesis (via acetyl-CoA carboxylase suppression) [3] and promotes stored-fat breakdown (via ADRB3 upregulation leading to hormone-sensitive lipase activation) [6]. Both effects were demonstrated in controlled preclinical experiments.

## Does AOD-9604 really work?

Animal studies demonstrated significant fat reduction [2][5][6]. Human Phase IIb pivotal trials showed good safety but did not meet the primary efficacy endpoint for weight loss at 24 weeks in 536 subjects [9]. A 2.6 kg versus 0.8 kg placebo signal was observed at 12 weeks in Phase IIa [8], but did not replicate to statistical significance in the larger, longer Phase IIb trial. The compound works in animals; it did not work to the regulatory threshold in humans at the doses studied.

## Does AOD-9604 work?

Strong in-vitro and rodent evidence supports the lipolytic mechanism [1][2][3][4][5][6]. Human efficacy data from the METAOD trial was insufficient for drug approval [9], though safety was well established across six trials [10]. The compound engages its target pathways; it did not produce statistically significant fat loss in the pivotal 24-week human trial.

## Why was AOD-9604 discontinued?

Clinical development was halted in 2007 because human efficacy data did not meet regulatory approval standards for a pharmaceutical drug, despite an excellent safety and tolerability profile indistinguishable from placebo [9]. The Phase IIb OPTIONS study (536 subjects, 24 weeks) failed its primary endpoint — no statistically significant body-mass reduction at any oral dose tested.

## Why was AOD-9604 discontinued as a drug?

FDA GRAS designation was granted for the nutraceutical pathway, but the pharmaceutical development program (METAOD) was stopped after Phase IIb failed to show adequate efficacy for drug approval [9][11]. The Phase IIa 12-week signal (2.6 kg vs 0.8 kg placebo at 1 mg/day) [8] was not reproduced to the required statistical threshold in the 24-week pivotal trial. Regulatory approval standards for obesity drugs require a defined minimum weight-loss advantage versus placebo; this threshold was not met.

## Is AOD-9604 FDA approved?

Not approved as a pharmaceutical drug for any human indication. AOD-9604 received FDA Generally Recognized as Safe (GRAS) designation as a nutraceutical ingredient for use in foods, beverages, and dietary supplements — as confirmed by Moré and Kenley (2014) [11]. GRAS status is distinct from pharmaceutical drug approval; it means the compound is considered safe for its intended nutraceutical use, not that it is an approved drug.

## How safe is AOD-9604?

Phase IIb trials with up to 1 mg/day over 24 weeks found safety and tolerability indistinguishable from placebo [10]. The most common adverse event was mild-to-moderate headache, occurring at similar rates in treatment and placebo arms. No serious adverse events, no treatment-related withdrawals, no IGF-1 elevation, no glucose effects, and no anti-AOD-9604 antibodies were detected in any of approximately 900 participants across six trials [10].

## Is AOD-9604 safe?

Phase I and Phase IIb data demonstrated a tolerability profile indistinguishable from placebo at doses up to 1 mg/day over 24 weeks [10]. No IGF-1 elevation or insulin effects were observed at any dose. Comprehensive preclinical toxicology (rat 6-month and cynomolgus monkey 9-month chronic studies, genotoxicology panels) found no signals of concern [11]. This is the most extensively documented aspect of the AOD-9604 literature.

## How long can you stay on AOD-9604?

The METAOD Phase IIb program studied doses over 24-week periods with no safety signals [9][10]. No controlled human data beyond that duration is available from the published record. The 24-week trial was the longest controlled human study conducted; what happens beyond that period in humans has not been formally studied.

## How long does it take for AOD-9604 to start working?

No validated human onset-of-action timeline exists in the published literature. Animal models show fat-mobilization effects accumulating over multi-week chronic treatment periods, consistent with the mechanism (ADRB3 upregulation requires sustained dosing) [5][6]. The earliest human efficacy measurement in the record was at 12 weeks — the Phase IIa assessment point [8].

## How much weight can you lose taking AOD-9604?

Human clinical trials did not demonstrate statistically significant weight loss versus placebo in the pivotal 24-week study [9]. The Phase IIa 12-week signal was 2.6 kg versus 0.8 kg placebo at 1 mg/day oral [8]. Rodent models showed meaningful reductions in body fat at various systemic doses across multiple obese-rodent lines [2][5]. The human record does not support a predictable weight-loss figure.

## How long does it take to see results from AOD-9604?

Human trial data did not show significant fat loss at the 24-week protocol endpoint [9]. The 12-week Phase IIa endpoint produced a 2.6 kg versus 0.8 kg placebo difference, but this was not reproduced in the pivotal trial [8]. Rodent data shows progressive fat reduction over several weeks of daily administration [5][6]. No human onset-of-effect timeline is established from controlled data.

## How many days a week should I take AOD-9604?

Research protocols used daily administration. The METAOD human trials used once-daily oral dosing throughout the trial period [9]. Five-days-on two-days-off cycling was used in some rodent studies. No comparative frequency study — daily versus alternate-day versus cycling — was conducted in humans; no published evidence supports one frequency over another for human use.

## How often should AOD-9604 be taken in research protocols?

Once-daily administration was the standard in the METAOD human trials [9]. Weekly intra-articular injection was the protocol in the rabbit osteoarthritis study [14]. No head-to-head frequency-comparison study was identified in the published human clinical literature reviewed for this site.

## When to take AOD-9604?

Clinical protocols administered oral doses once daily. Some animal studies used pre-exercise timing to assess lipolytic synergy with exercise-induced metabolic demands. No published clinical study compared timing conditions (morning-fasted versus evening versus fed) in humans. No timing-comparison data from human controlled trials was identified in the literature reviewed.

## Where to inject AOD-9604?

Subcutaneous injection was the primary route for injectable research use; it delivers higher peptide bioavailability than oral administration. Oral tablet was the route used in all METAOD human clinical trials for the obesity indication [9]. Intra-articular injection (joint-space injection, ultrasound-guided) was the route used in the rabbit OA study [14] and is the route being investigated in the NCT07225829 human Phase 2a OA trial. No comparative bioavailability study between subcutaneous and oral routes in humans was identified in the published literature.

## How to reconstitute AOD-9604?

Research protocols typically describe dissolving lyophilized AOD-9604 in bacteriostatic water or dilute acetic acid at a concentration of 1–2 mg/mL for injection-route studies. Lyophilized powder is stable at room temperature for extended periods. Reconstituted solution should be refrigerated at 2–8°C and used within 28 days per standard peptide-handling protocols. No AOD-9604-specific reconstitution study was identified in the published primary literature; this guidance reflects standard-of-practice for research-use peptides.

## Does AOD-9604 need to be refrigerated?

Lyophilized (freeze-dried) powder is stable at room temperature for extended periods per standard peptide handling. Reconstituted peptide solution requires refrigeration at 2–8°C and should be used within 28 days of reconstitution per standard peptide handling protocols. These are industry-standard stability guidelines, not AOD-9604-specific data from a published primary study.

## What is hGH fragment 176-191?

The C-terminal 16-amino-acid segment of human growth hormone, corresponding to residues 176–191 (identified as Tyr-hGH177–191 in the AOD-9604 form). This region was identified as the functional lipolytic domain of hGH in early Monash University studies by Ng and colleagues [1][3]. AOD-9604 is the synthetic analogue of this fragment with a tyrosine substituted at the N-terminal position of the original phenylalanine.

## Can you take AOD-9604 with tirzepatide?

No published clinical data exists on co-administration of AOD-9604 with tirzepatide or other GLP-1/GIP receptor agonists. The mechanisms are distinct — AOD-9604 acts on adipocyte lipogenesis and lipolysis pathways, while tirzepatide acts on incretin signaling (GIP and GLP-1 receptors) to modulate appetite and insulin secretion. No combination study was identified in the published literature reviewed for this site.

## What peptide is most effective for fat loss research?

Head-to-head comparisons in published research are limited. AOD-9604 is documented as unique in its selective lipolysis without IGF-1 activation — a distinction setting it apart from full-length hGH and GHRH analogues in the research literature [5][10]. Whether any specific peptide is most 'effective' for fat-loss research is not established by head-to-head controlled comparison data in the published primary literature reviewed.

## AOD-9604 research cost context

Pricing varies by supplier, purity grade, and quantity. This site does not provide vendor pricing, recommendations, or sourcing guidance. Reviews AOD-9604 is an editorial literature digest — it catalogs the research record, not commercial supply information. Registered research chemical suppliers maintain current pricing for research-grade material.

---

The AOD-9604 record, reduced to essentials — six human trials catalogued, primary endpoint outcome stated, no clinic and no prescription on the premises.